BRCA1 and ovarian serous adenocarcinoma: The study included 2478 of a triple-negative breast cancers (TNBCs) and 3493 high-grade serous ovarian cancers (HGSOCs) cases and controls without a germline pathogenic variant of BRCA1 and concluded that testing for BRCA1 epimutation in blood may have implications in cancer prediction.